Oligoclonal nanobody-based recombinant antivenom protects mice challenged with venom from cobras and king cobras from India

The study shows the antivenom can neutralize toxins from multiple cobra species in a single formulation. Rediff, News‑Medical and Medical Xpress reported that the antivenom uses engineered nanobodies—small, single‑domain antibodies—arranged in an oligoclonal mixture to target a spectrum of cobra neurotoxins.

Science | AAAS and The Conversation highlighted the recombinant approach as a departure from conventional serum‑derived therapies, noting its potential for scalable manufacturing and reduced animal use. The coverage stresses the breadth of protection offered against both common and less‑studied cobra venoms.

The research team intends to move to pre‑clinical safety studies and, pending results, initiate human trials to evaluate therapeutic value for snakebite victims. Monitoring will focus on translating mouse protection into clinical outcomes and on regulatory pathways for a new class of antivenom.